ES2906379T3 - Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos - Google Patents
Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos Download PDFInfo
- Publication number
- ES2906379T3 ES2906379T3 ES16785611T ES16785611T ES2906379T3 ES 2906379 T3 ES2906379 T3 ES 2906379T3 ES 16785611 T ES16785611 T ES 16785611T ES 16785611 T ES16785611 T ES 16785611T ES 2906379 T3 ES2906379 T3 ES 2906379T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- compound
- mmol
- disease
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 293
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
- 238000000034 method Methods 0.000 title description 30
- 239000000556 agonist Substances 0.000 title description 14
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 60
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 31
- 239000001257 hydrogen Substances 0.000 claims abstract description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 24
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 23
- 150000002367 halogens Chemical group 0.000 claims abstract description 23
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 15
- 125000002541 furyl group Chemical group 0.000 claims abstract description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 12
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims abstract description 8
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims abstract description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 5
- 150000002431 hydrogen Chemical group 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 64
- 201000010099 disease Diseases 0.000 claims description 45
- 238000011282 treatment Methods 0.000 claims description 29
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 24
- 210000003205 muscle Anatomy 0.000 claims description 21
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 19
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 15
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 9
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims description 9
- 208000030159 metabolic disease Diseases 0.000 claims description 9
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 230000003647 oxidation Effects 0.000 claims description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 6
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 claims description 6
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 6
- 229910052731 fluorine Chemical group 0.000 claims description 6
- 239000011737 fluorine Chemical group 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 208000019553 vascular disease Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000012268 mitochondrial disease Diseases 0.000 claims description 5
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 4
- 208000010428 Muscle Weakness Diseases 0.000 claims description 4
- 206010028372 Muscular weakness Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000013234 Pearson syndrome Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000016097 disease of metabolism Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 201000009035 MERRF syndrome Diseases 0.000 claims description 3
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 3
- 206010049565 Muscle fatigue Diseases 0.000 claims description 3
- 208000014245 Ocular vascular disease Diseases 0.000 claims description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 3
- 208000006443 lactic acidosis Diseases 0.000 claims description 3
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 3
- 230000003387 muscular Effects 0.000 claims description 3
- 230000001272 neurogenic effect Effects 0.000 claims description 3
- 230000008555 neuronal activation Effects 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 208000035177 MELAS Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 abstract description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 129
- 230000015572 biosynthetic process Effects 0.000 description 129
- 238000003786 synthesis reaction Methods 0.000 description 128
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 122
- 239000011541 reaction mixture Substances 0.000 description 105
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 97
- 238000005160 1H NMR spectroscopy Methods 0.000 description 75
- 239000000243 solution Substances 0.000 description 75
- 238000002474 experimental method Methods 0.000 description 61
- 238000006243 chemical reaction Methods 0.000 description 60
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 53
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 53
- 235000019439 ethyl acetate Nutrition 0.000 description 52
- 235000002639 sodium chloride Nutrition 0.000 description 45
- 239000000203 mixture Substances 0.000 description 43
- 239000007787 solid Substances 0.000 description 41
- 239000012299 nitrogen atmosphere Substances 0.000 description 39
- 239000007832 Na2SO4 Substances 0.000 description 38
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 38
- 229910052938 sodium sulfate Inorganic materials 0.000 description 38
- 235000011152 sodium sulphate Nutrition 0.000 description 38
- 238000004293 19F NMR spectroscopy Methods 0.000 description 34
- 239000000284 extract Substances 0.000 description 34
- -1 -OH Chemical group 0.000 description 33
- 239000012267 brine Substances 0.000 description 26
- 238000004128 high performance liquid chromatography Methods 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 238000010828 elution Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000005457 ice water Substances 0.000 description 14
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- KEQLCUZKLBSQTD-MRVPVSSYSA-N ethyl (3R)-6-bromo-3-methylhexanoate Chemical compound BrCCC[C@H](CC(=O)OCC)C KEQLCUZKLBSQTD-MRVPVSSYSA-N 0.000 description 12
- 206010016654 Fibrosis Diseases 0.000 description 11
- 230000004761 fibrosis Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 108010015181 PPAR delta Proteins 0.000 description 10
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 10
- PXJACNDVRNAFHD-UHFFFAOYSA-N (2-methoxyphenyl)methanamine Chemical compound COC1=CC=CC=C1CN PXJACNDVRNAFHD-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 206010028851 Necrosis Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 210000001087 myotubule Anatomy 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 230000008437 mitochondrial biogenesis Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 229910015845 BBr3 Inorganic materials 0.000 description 5
- QZWQLFCJTVVBIU-UHFFFAOYSA-N CC1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)C(F)(F)F Chemical compound CC1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)C(F)(F)F QZWQLFCJTVVBIU-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 5
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 description 5
- 206010061481 Renal injury Diseases 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 208000037806 kidney injury Diseases 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 108020001756 ligand binding domains Proteins 0.000 description 5
- ADENVXCOJGUNQE-UHFFFAOYSA-N n-prop-2-ynyl-4-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=C(C(=O)NCC#C)C=C1 ADENVXCOJGUNQE-UHFFFAOYSA-N 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- GJWSUKYXUMVMGX-UHFFFAOYSA-N (+)-(R)-citronellic acid Natural products OC(=O)CC(C)CCC=C(C)C GJWSUKYXUMVMGX-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- OMCDNQOMTAHLDT-UHFFFAOYSA-N CC1=CN=C(N1CC1=C(C=CC=C1)O)C=1C=NC(=CC=1)C(F)(F)F Chemical compound CC1=CN=C(N1CC1=C(C=CC=C1)O)C=1C=NC(=CC=1)C(F)(F)F OMCDNQOMTAHLDT-UHFFFAOYSA-N 0.000 description 4
- WNDPXYAVRBQZAL-UHFFFAOYSA-N COC1=C(CN2C(=NC=C2C)C=2C=CC(=NC=2)C(F)(F)F)C=CC=C1 Chemical compound COC1=C(CN2C(=NC=C2C)C=2C=CC(=NC=2)C(F)(F)F)C=CC=C1 WNDPXYAVRBQZAL-UHFFFAOYSA-N 0.000 description 4
- UKKFYSLMACHPAJ-UHFFFAOYSA-N COC1=C(CN2C(C)=CN=C2C2=CC=C(C=C2)C(F)(F)F)C=CC=C1 Chemical compound COC1=C(CN2C(C)=CN=C2C2=CC=C(C=C2)C(F)(F)F)C=CC=C1 UKKFYSLMACHPAJ-UHFFFAOYSA-N 0.000 description 4
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 4
- 208000016192 Demyelinating disease Diseases 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- GZOBAVBBIIMOMF-QGZVFWFLSA-N FC(C1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1)F Chemical compound FC(C1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1)F GZOBAVBBIIMOMF-QGZVFWFLSA-N 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000029578 Muscle disease Diseases 0.000 description 4
- 208000029549 Muscle injury Diseases 0.000 description 4
- 208000033626 Renal failure acute Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 201000011040 acute kidney failure Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 229960002591 hydroxyproline Drugs 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229960003194 meglumine Drugs 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 230000009756 muscle regeneration Effects 0.000 description 4
- 201000006938 muscular dystrophy Diseases 0.000 description 4
- SCMZYNODBBJLAB-UHFFFAOYSA-N n-prop-2-ynyl-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=C(C(=O)NCC#C)C=N1 SCMZYNODBBJLAB-UHFFFAOYSA-N 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000003314 quadriceps muscle Anatomy 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- CUVCBLWSYZWJDZ-UHFFFAOYSA-N 2-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]imidazol-1-yl]methyl]phenol Chemical compound CC1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)OC(F)(F)F CUVCBLWSYZWJDZ-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NCAIVHUTUKZEIG-UHFFFAOYSA-N CC(C(=O)O)(CCCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F)C Chemical compound CC(C(=O)O)(CCCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F)C NCAIVHUTUKZEIG-UHFFFAOYSA-N 0.000 description 3
- OOQYTUDCOJNPET-UHFFFAOYSA-N COC1=C(CN2C(=NC=C2)C=2C=CC(=NC=2)C(F)(F)F)C=CC=C1 Chemical compound COC1=C(CN2C(=NC=C2)C=2C=CC(=NC=2)C(F)(F)F)C=CC=C1 OOQYTUDCOJNPET-UHFFFAOYSA-N 0.000 description 3
- FVHFOYRHJUFWFT-ZMAHMCKTSA-N C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C([2H])([2H])[2H])C=1C=NC(=CC=1)C(F)(F)F Chemical compound C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C([2H])([2H])[2H])C=1C=NC(=CC=1)C(F)(F)F FVHFOYRHJUFWFT-ZMAHMCKTSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- 238000012311 Shapiro-Wilk normality test Methods 0.000 description 3
- 208000004350 Strabismus Diseases 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000009338 distal myopathy Diseases 0.000 description 3
- CSQGAUJUODHNIM-UHFFFAOYSA-N ethyl 6-bromo-2,2-dimethylhexanoate Chemical compound CCOC(=O)C(C)(C)CCCCBr CSQGAUJUODHNIM-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 230000004898 mitochondrial function Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- LAWLETDOJIIYNQ-UHFFFAOYSA-N n-prop-2-ynyl-4-(trifluoromethoxy)benzamide Chemical compound FC(F)(F)OC1=CC=C(C(=O)NCC#C)C=C1 LAWLETDOJIIYNQ-UHFFFAOYSA-N 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 238000001422 normality test Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- NOYASZMZIBFFNZ-UHFFFAOYSA-N (2-bromophenyl)methanamine Chemical compound NCC1=CC=CC=C1Br NOYASZMZIBFFNZ-UHFFFAOYSA-N 0.000 description 2
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 2
- UTOIEVWJKDLJGE-AQRBRUGDSA-N (4r,6s)-6-[(e)-2-[4-(4-fluorophenyl)-2,6-di(propan-2-yl)pyrimidin-5-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C=1C=C(F)C=CC=1C1=NC(C(C)C)=NC(C(C)C)=C1\C=C\[C@@H]1C[C@@H](O)CC(=O)O1 UTOIEVWJKDLJGE-AQRBRUGDSA-N 0.000 description 2
- GJWSUKYXUMVMGX-SECBINFHSA-N (R)-citronellic acid Chemical compound OC(=O)C[C@H](C)CCC=C(C)C GJWSUKYXUMVMGX-SECBINFHSA-N 0.000 description 2
- NEHNMFOYXAPHSD-JTQLQIEISA-N (S)-(-)-Citronellal Chemical compound O=CC[C@@H](C)CCC=C(C)C NEHNMFOYXAPHSD-JTQLQIEISA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- GJWSUKYXUMVMGX-VIFPVBQESA-N (S)-citronellic acid Chemical compound OC(=O)C[C@@H](C)CCC=C(C)C GJWSUKYXUMVMGX-VIFPVBQESA-N 0.000 description 2
- WAUNFWSVXRPCDQ-UHFFFAOYSA-N 1-(bromomethyl)-2-methoxybenzene Chemical compound COC1=CC=CC=C1CBr WAUNFWSVXRPCDQ-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- YJCNPPLLNNZSJA-UHFFFAOYSA-N 1-[(2-methoxyphenyl)methyl]-5-methyl-2-[4-(trifluoromethoxy)phenyl]imidazole Chemical compound COC1=C(CN2C(C)=CN=C2C2=CC=C(OC(F)(F)F)C=C2)C=CC=C1 YJCNPPLLNNZSJA-UHFFFAOYSA-N 0.000 description 2
- LSMUKUCFYSRTBG-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-5-methyl-1-[[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]imidazole Chemical compound CC1=CN=C(N1CC1=C(C=CC=C1)B1OC(C)(C)C(C)(C)O1)C1=CC=C(OC(F)F)C=C1 LSMUKUCFYSRTBG-UHFFFAOYSA-N 0.000 description 2
- CLEFEKBQZOFZIF-UHFFFAOYSA-N 2-[4-(difluoromethyl)phenyl]-5-methyl-1-[[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]imidazole Chemical compound CC1=CN=C(N1CC1=C(C=CC=C1)B1OC(C)(C)C(C)(C)O1)C1=CC=C(C=C1)C(F)F CLEFEKBQZOFZIF-UHFFFAOYSA-N 0.000 description 2
- SWDKWZQLMUSLRH-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]-1h-imidazole Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NC=CN1 SWDKWZQLMUSLRH-UHFFFAOYSA-N 0.000 description 2
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 2
- HVAPLSNCVYXFDQ-UHFFFAOYSA-N 3,3-dimethyl-1-(trifluoromethyl)-1$l^{3},2-benziodoxole Chemical compound C1=CC=C2C(C)(C)OI(C(F)(F)F)C2=C1 HVAPLSNCVYXFDQ-UHFFFAOYSA-N 0.000 description 2
- NZQMQVJXSRMTCJ-UHFFFAOYSA-N 3-Methyl-hexanoic acid Chemical compound CCCC(C)CC(O)=O NZQMQVJXSRMTCJ-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- MTTGBJUPTVODIM-UHFFFAOYSA-N 4-(difluoromethoxy)-n-prop-2-ynylbenzamide Chemical compound FC(F)OC1=CC=C(C(=O)NCC#C)C=C1 MTTGBJUPTVODIM-UHFFFAOYSA-N 0.000 description 2
- HVGGGWWCXFNXPI-UHFFFAOYSA-N 4-chloro-n-prop-2-ynylbenzamide Chemical compound ClC1=CC=C(C(=O)NCC#C)C=C1 HVGGGWWCXFNXPI-UHFFFAOYSA-N 0.000 description 2
- NXBDZSMRZFFVBA-UHFFFAOYSA-N 4-fluoro-n-prop-2-ynylbenzamide Chemical compound FC1=CC=C(C(=O)NCC#C)C=C1 NXBDZSMRZFFVBA-UHFFFAOYSA-N 0.000 description 2
- HHGZOEBSPZSATM-UHFFFAOYSA-N 4-methylsulfanyl-n-prop-2-ynylbenzamide Chemical compound CSC1=CC=C(C(=O)NCC#C)C=C1 HHGZOEBSPZSATM-UHFFFAOYSA-N 0.000 description 2
- SWKPKONEIZGROQ-UHFFFAOYSA-N 4-trifluoromethylbenzoic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=C1 SWKPKONEIZGROQ-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- JNYLMODTPLSLIF-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)N=C1 JNYLMODTPLSLIF-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- FEFPYRHSFYLOOH-UHFFFAOYSA-N BrC1=CN=C(N1CC1=C(C=CC=C1)OC)C1=CC=C(C=C1)C(F)(F)F Chemical compound BrC1=CN=C(N1CC1=C(C=CC=C1)OC)C1=CC=C(C=C1)C(F)(F)F FEFPYRHSFYLOOH-UHFFFAOYSA-N 0.000 description 2
- UXUZSRCJMPRAPX-UHFFFAOYSA-N BrC1=CN=C(N1CC1=C(C=CC=C1)OC)C=1C=CC(=NC=1)C(F)(F)F Chemical compound BrC1=CN=C(N1CC1=C(C=CC=C1)OC)C=1C=CC(=NC=1)C(F)(F)F UXUZSRCJMPRAPX-UHFFFAOYSA-N 0.000 description 2
- QZWQLFCJTVVBIU-FIBGUPNXSA-N C(C1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)C(F)(F)F)([2H])([2H])[2H] Chemical compound C(C1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)C(F)(F)F)([2H])([2H])[2H] QZWQLFCJTVVBIU-FIBGUPNXSA-N 0.000 description 2
- OMCDNQOMTAHLDT-FIBGUPNXSA-N C(C1=CN=C(N1CC1=C(C=CC=C1)O)C=1C=NC(=CC=1)C(F)(F)F)([2H])([2H])[2H] Chemical compound C(C1=CN=C(N1CC1=C(C=CC=C1)O)C=1C=NC(=CC=1)C(F)(F)F)([2H])([2H])[2H] OMCDNQOMTAHLDT-FIBGUPNXSA-N 0.000 description 2
- HACGKBBHYYAQQF-UHFFFAOYSA-N CC1=CN=C(N1CC1=C(Br)C=CC=C1)C1=CC=C(C=C1)C(F)F Chemical compound CC1=CN=C(N1CC1=C(Br)C=CC=C1)C1=CC=C(C=C1)C(F)F HACGKBBHYYAQQF-UHFFFAOYSA-N 0.000 description 2
- ULPLVTSBISQVDW-UHFFFAOYSA-N CC1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)C Chemical compound CC1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)C ULPLVTSBISQVDW-UHFFFAOYSA-N 0.000 description 2
- HMNAPLQUTZADTN-UHFFFAOYSA-N CC1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)SC Chemical compound CC1=CN=C(N1CC1=C(C=CC=C1)O)C1=CC=C(C=C1)SC HMNAPLQUTZADTN-UHFFFAOYSA-N 0.000 description 2
- UOEKCBOENFGRLG-UHFFFAOYSA-N CC1=CN=C(N1CC1=C(Cl)C=CC=C1)C1=CC=C(OC(F)F)C=C1 Chemical compound CC1=CN=C(N1CC1=C(Cl)C=CC=C1)C1=CC=C(OC(F)F)C=C1 UOEKCBOENFGRLG-UHFFFAOYSA-N 0.000 description 2
- UKKFYSLMACHPAJ-FIBGUPNXSA-N COC1=C(CN2C(=NC=C2C([2H])([2H])[2H])C2=CC=C(C=C2)C(F)(F)F)C=CC=C1 Chemical compound COC1=C(CN2C(=NC=C2C([2H])([2H])[2H])C2=CC=C(C=C2)C(F)(F)F)C=CC=C1 UKKFYSLMACHPAJ-FIBGUPNXSA-N 0.000 description 2
- WNDPXYAVRBQZAL-FIBGUPNXSA-N COC1=C(CN2C(=NC=C2C([2H])([2H])[2H])C=2C=CC(=NC=2)C(F)(F)F)C=CC=C1 Chemical compound COC1=C(CN2C(=NC=C2C([2H])([2H])[2H])C=2C=CC(=NC=2)C(F)(F)F)C=CC=C1 WNDPXYAVRBQZAL-FIBGUPNXSA-N 0.000 description 2
- JDBKDVARMHDHEK-UHFFFAOYSA-N COC1=C(CN2C(C)=CN=C2C2=CC=C(C)C=C2)C=CC=C1 Chemical compound COC1=C(CN2C(C)=CN=C2C2=CC=C(C)C=C2)C=CC=C1 JDBKDVARMHDHEK-UHFFFAOYSA-N 0.000 description 2
- PHFHDUSAONDBHH-UHFFFAOYSA-N COC1=C(CN2C=CN=C2C2=CC=C(C=C2)C(F)(F)F)C=CC=C1 Chemical compound COC1=C(CN2C=CN=C2C2=CC=C(C=C2)C(F)(F)F)C=CC=C1 PHFHDUSAONDBHH-UHFFFAOYSA-N 0.000 description 2
- SKVCAEHZKNWAQZ-UHFFFAOYSA-N CSC1=CC=C(C=C1)C1=NC=C(C)N1CC1=C(Br)C=CC=C1 Chemical compound CSC1=CC=C(C=C1)C1=NC=C(C)N1CC1=C(Br)C=CC=C1 SKVCAEHZKNWAQZ-UHFFFAOYSA-N 0.000 description 2
- IGEYBBZLLOTKIF-LJQANCHMSA-N C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C Chemical compound C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C IGEYBBZLLOTKIF-LJQANCHMSA-N 0.000 description 2
- FMOPHFSPINWSOV-QGZVFWFLSA-N C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F Chemical compound C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F FMOPHFSPINWSOV-QGZVFWFLSA-N 0.000 description 2
- PASBPZUWNUNJHE-GOSISDBHSA-N C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)SC Chemical compound C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)SC PASBPZUWNUNJHE-GOSISDBHSA-N 0.000 description 2
- FMOPHFSPINWSOV-KRWDZBQOSA-N C[C@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F Chemical compound C[C@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F FMOPHFSPINWSOV-KRWDZBQOSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 2
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- DVSOWTHUYYMROI-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O)F Chemical compound ClC1=C(C=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O)F DVSOWTHUYYMROI-UHFFFAOYSA-N 0.000 description 2
- AAXVGCQJHPUCKW-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)OC)F Chemical compound ClC1=C(C=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)OC)F AAXVGCQJHPUCKW-UHFFFAOYSA-N 0.000 description 2
- GCESMSWRWMRRHD-UHFFFAOYSA-N ClC1=C(C=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCCCC(C(=O)O)(C)C)C=CC=C1)F Chemical compound ClC1=C(C=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCCCC(C(=O)O)(C)C)C=CC=C1)F GCESMSWRWMRRHD-UHFFFAOYSA-N 0.000 description 2
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 2
- MUHAFFSXFYIHJM-QGZVFWFLSA-N ClC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1 Chemical compound ClC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1 MUHAFFSXFYIHJM-QGZVFWFLSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000001039 Dystrophin Human genes 0.000 description 2
- 108010069091 Dystrophin Proteins 0.000 description 2
- 102100034239 Emerin Human genes 0.000 description 2
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- PDIANGAPEBVNHN-UHFFFAOYSA-N FC(C1=CC=C(C(=O)NCC#C)C=C1)F Chemical compound FC(C1=CC=C(C(=O)NCC#C)C=C1)F PDIANGAPEBVNHN-UHFFFAOYSA-N 0.000 description 2
- LJNHWBQXFHWTAE-UHFFFAOYSA-N FC(C1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O)F Chemical compound FC(C1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O)F LJNHWBQXFHWTAE-UHFFFAOYSA-N 0.000 description 2
- FCDMNOQYZJZVGW-UHFFFAOYSA-N FC1=CC(=C(C=C1)O)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F Chemical compound FC1=CC(=C(C=C1)O)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F FCDMNOQYZJZVGW-UHFFFAOYSA-N 0.000 description 2
- XJDLMVBBVWSTEO-UHFFFAOYSA-N FC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O Chemical compound FC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O XJDLMVBBVWSTEO-UHFFFAOYSA-N 0.000 description 2
- FIYZTKRBIJNZGH-UHFFFAOYSA-N FC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)OC Chemical compound FC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)OC FIYZTKRBIJNZGH-UHFFFAOYSA-N 0.000 description 2
- OAEPLYNAKJZLSC-QGZVFWFLSA-N FC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1 Chemical compound FC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1 OAEPLYNAKJZLSC-QGZVFWFLSA-N 0.000 description 2
- ZRDBAAOJROODQL-UHFFFAOYSA-N FC=1C=C(C(=O)NCC#C)C=CC=1C(F)(F)F Chemical compound FC=1C=C(C(=O)NCC#C)C=CC=1C(F)(F)F ZRDBAAOJROODQL-UHFFFAOYSA-N 0.000 description 2
- LSAQKOLJZVZIGV-UHFFFAOYSA-N FC=1C=C(C=CC=1C(F)(F)F)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)OC Chemical compound FC=1C=C(C=CC=1C(F)(F)F)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)OC LSAQKOLJZVZIGV-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241001559542 Hippocampus hippocampus Species 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010069825 Myoclonic epilepsy and ragged-red fibres Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- QACOEHQFENZDIO-UHFFFAOYSA-N N1C(=NCC1)C=1C=CC(=NC=1)C(F)(F)F Chemical compound N1C(=NCC1)C=1C=CC(=NC=1)C(F)(F)F QACOEHQFENZDIO-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000032978 Structural Congenital Myopathies Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 2
- 230000004308 accommodation Effects 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KSCRVOKQPYZBHZ-IXPOFIJOSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(C)C)C(=O)OCC1=CC=CC=C1 KSCRVOKQPYZBHZ-IXPOFIJOSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- DLLJVQNYBYOKGS-UHFFFAOYSA-N ethoxyethane;pentane Chemical compound CCCCC.CCOCC DLLJVQNYBYOKGS-UHFFFAOYSA-N 0.000 description 2
- BUZPORNLCIEDRH-YHMJZVADSA-N ethyl (3R)-5-(3,3-dimethyloxiran-2-yl)-3-methylpentanoate Chemical compound CC1(C(O1)CC[C@H](CC(=O)OCC)C)C BUZPORNLCIEDRH-YHMJZVADSA-N 0.000 description 2
- FUSUZUAOTBPQAB-LJQANCHMSA-N ethyl (3R)-6-[2-[[2-(4-chlorophenyl)-5-methylimidazol-1-yl]methyl]phenoxy]-3-methylhexanoate Chemical compound ClC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)OCC)C)C=CC=C1 FUSUZUAOTBPQAB-LJQANCHMSA-N 0.000 description 2
- UMIQLFHOIFFCQC-LJQANCHMSA-N ethyl (3R)-6-[2-[[2-(4-fluorophenyl)-5-methylimidazol-1-yl]methyl]phenoxy]-3-methylhexanoate Chemical compound FC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)OCC)C)C=CC=C1 UMIQLFHOIFFCQC-LJQANCHMSA-N 0.000 description 2
- UFPASQFPTYKYJI-VIFPVBQESA-N ethyl (3S)-3-methyl-6-methylsulfonyloxyhexanoate Chemical compound C[C@H](CC(=O)OCC)CCCOS(=O)(=O)C UFPASQFPTYKYJI-VIFPVBQESA-N 0.000 description 2
- BUZPORNLCIEDRH-RGURZIINSA-N ethyl (3S)-5-(3,3-dimethyloxiran-2-yl)-3-methylpentanoate Chemical compound CC1(C(O1)CC[C@@H](CC(=O)OCC)C)C BUZPORNLCIEDRH-RGURZIINSA-N 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 206010028320 muscle necrosis Diseases 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 206010030875 ophthalmoplegia Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 201000010866 very long chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 2
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
- MNULEGDCPYONBU-UIXCWHRQSA-N (1R,4E,5'S,6S,6'S,7R,8S,10R,11R,12S,14R,15S,16R,18Z,20Z,22R,25S,27R,28S,29R)-22-ethyl-7,11,14,15-tetrahydroxy-6'-[(2R)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC[C@@H]1CC[C@@H]2O[C@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)[C@@H](C)[C@H](OC(=O)\C=C\[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C\C=C/C=C\1)[C@@H]2C MNULEGDCPYONBU-UIXCWHRQSA-N 0.000 description 1
- MNULEGDCPYONBU-CBLVMMTCSA-N (1R,4Z,5'S,6S,6'S,7R,8S,10R,11R,12S,14R,15S,16R,18Z,20Z,22R,25S,27R,28S,29R)-22-ethyl-7,11,14,15-tetrahydroxy-6'-[(2R)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC[C@@H]1CC[C@@H]2O[C@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)[C@@H](C)[C@H](OC(=O)\C=C/[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C\C=C/C=C\1)[C@@H]2C MNULEGDCPYONBU-CBLVMMTCSA-N 0.000 description 1
- MNULEGDCPYONBU-WABYXMGOSA-N (1S,4E,5'R,6R,6'R,7S,8R,10S,11S,12R,14S,15R,16S,18E,22S,25R,27S,28R,29S)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC[C@H]1CC[C@H]2O[C@@]3(CC[C@@H](C)[C@@H](CC(C)O)O3)[C@H](C)[C@@H](OC(=O)\C=C\[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@](C)(O)[C@H](O)[C@@H](C)C\C=C\C=C1)[C@H]2C MNULEGDCPYONBU-WABYXMGOSA-N 0.000 description 1
- MNULEGDCPYONBU-QECWTJOCSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-QECWTJOCSA-N 0.000 description 1
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
- MNULEGDCPYONBU-BOXGPLBDSA-N (1r,4s,5e,5'r,6'r,7e,10s,11s,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-BOXGPLBDSA-N 0.000 description 1
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 1
- XQXMDYVBIZPDHE-UHFFFAOYSA-N (2-methoxy-5-methylphenyl)methanamine Chemical compound COC1=CC=C(C)C=C1CN XQXMDYVBIZPDHE-UHFFFAOYSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- MNULEGDCPYONBU-YOKYSHDFSA-N (5'R,10S,11R,12S,14S,15R,16R,18R,19S,20R,26R,29S)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2S)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C=CC(=O)OC([C@H]1C)[C@H]2C)C=CC=CC(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-YOKYSHDFSA-N 0.000 description 1
- IYQIJUZZRLPXIL-UHFFFAOYSA-N (5-fluoro-2-methoxyphenyl)methanamine Chemical compound COC1=CC=C(F)C=C1CN IYQIJUZZRLPXIL-UHFFFAOYSA-N 0.000 description 1
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 235000012121 (S)-(-)-citronellal Nutrition 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GPCJDSXBRMKASP-UHFFFAOYSA-N 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid Chemical compound OC(=O)C(Cl)(Cl)CCCCCCCCCCC1=CC=C(Cl)C=C1 GPCJDSXBRMKASP-UHFFFAOYSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- XYDNTALWFYHWQB-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1h-imidazole Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NCCN1 XYDNTALWFYHWQB-UHFFFAOYSA-N 0.000 description 1
- ZUGQWAYOWCBWGM-UHFFFAOYSA-N 2-[4-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound CC=1N=C(C=2C(=CC(=CC=2)C(F)(F)F)F)SC=1CSC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 ZUGQWAYOWCBWGM-UHFFFAOYSA-N 0.000 description 1
- HRPKMEWDMLPBGU-UHFFFAOYSA-N 2-[[2-[4-(furan-2-yl)phenyl]-5-methylimidazol-1-yl]methyl]phenol Chemical compound O1C(=CC=C1)C1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O HRPKMEWDMLPBGU-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- HRIHSNPFVGMAKX-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C(F)=C1 HRIHSNPFVGMAKX-UHFFFAOYSA-N 0.000 description 1
- BSNNYLYELGBSBA-UHFFFAOYSA-N 4-(difluoromethoxy)benzoic acid Chemical compound OC(=O)C1=CC=C(OC(F)F)C=C1 BSNNYLYELGBSBA-UHFFFAOYSA-N 0.000 description 1
- AVYXJQFZBUXNHB-UHFFFAOYSA-N 4-(difluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(C(F)F)C=C1 AVYXJQFZBUXNHB-UHFFFAOYSA-N 0.000 description 1
- RATSANVPHHXDCT-UHFFFAOYSA-N 4-(trifluoromethoxy)benzoic acid Chemical compound OC(=O)C1=CC=C(OC(F)(F)F)C=C1 RATSANVPHHXDCT-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- HYGJKOLKSPIJLO-UHFFFAOYSA-N 4-chloro-3-fluoro-N-prop-2-ynylbenzamide Chemical compound ClC1=C(C=C(C(=O)NCC#C)C=C1)F HYGJKOLKSPIJLO-UHFFFAOYSA-N 0.000 description 1
- QPIBHIXKUQKNFP-UHFFFAOYSA-N 4-chloro-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C(F)=C1 QPIBHIXKUQKNFP-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 1
- 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 description 1
- KWHCPERWLHBLOT-UHFFFAOYSA-N 4-methylsulfanylbenzoic acid Chemical compound CSC1=CC=C(C(O)=O)C=C1 KWHCPERWLHBLOT-UHFFFAOYSA-N 0.000 description 1
- BVYFUUWYVRDPNQ-UHFFFAOYSA-N 5-(1h-imidazol-2-yl)-2-(trifluoromethyl)pyridine Chemical compound C1=NC(C(F)(F)F)=CC=C1C1=NC=CN1 BVYFUUWYVRDPNQ-UHFFFAOYSA-N 0.000 description 1
- QCRGNZDQWCIWNH-UHFFFAOYSA-N 5-methyl-2-(4-methylsulfanylphenyl)-1-[[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]imidazole Chemical compound CSC1=CC=C(C=C1)C1=NC=C(C)N1CC1=C(C=CC=C1)B1OC(C)(C)C(C)(C)O1 QCRGNZDQWCIWNH-UHFFFAOYSA-N 0.000 description 1
- MRPAGRCGPAXOGS-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=N1 MRPAGRCGPAXOGS-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 208000036022 Alpers' disease Diseases 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 1
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000012904 Bartter disease Diseases 0.000 description 1
- 208000010062 Bartter syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Chemical class 0.000 description 1
- 208000006304 Bethlem myopathy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UETWPXKPFLUIMG-UHFFFAOYSA-N BrC=1N=C(N(C=1)CC1=C(C=CC=C1)OC)C=1C=CC(=NC=1)C(F)(F)F Chemical compound BrC=1N=C(N(C=1)CC1=C(C=CC=C1)OC)C=1C=CC(=NC=1)C(F)(F)F UETWPXKPFLUIMG-UHFFFAOYSA-N 0.000 description 1
- CMNJJUDCRVHODH-UHFFFAOYSA-N BrC=1N=C(N(C=1Br)CC1=C(C=CC=C1)OC)C=1C=CC(=NC=1)C(F)(F)F Chemical compound BrC=1N=C(N(C=1Br)CC1=C(C=CC=C1)OC)C=1C=CC(=NC=1)C(F)(F)F CMNJJUDCRVHODH-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 1
- WZXLXBCEKMSYLR-UHFFFAOYSA-N CC(C(=O)OCC)(CCCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F)C Chemical compound CC(C(=O)OCC)(CCCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F)C WZXLXBCEKMSYLR-UHFFFAOYSA-N 0.000 description 1
- PTMRJDTVDCAPQL-UHFFFAOYSA-N CC1=CC(=C(C=C1)O)CN1C(=NC=C1C)C1=CC=C(C=C1)OC(F)(F)F Chemical compound CC1=CC(=C(C=C1)O)CN1C(=NC=C1C)C1=CC=C(C=C1)OC(F)(F)F PTMRJDTVDCAPQL-UHFFFAOYSA-N 0.000 description 1
- MNULEGDCPYONBU-MQLHLVDXSA-N CC[C@@H]1CC[C@@H]2O[C@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)[C@@H](C)[C@H](OC(=O)\C=C\[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C\C=C\C=C\1)C2C Polymers CC[C@@H]1CC[C@@H]2O[C@]3(CC[C@H](C)[C@H](C[C@@H](C)O)O3)[C@@H](C)[C@H](OC(=O)\C=C\[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@](C)(O)[C@@H](O)[C@H](C)C\C=C\C=C\1)C2C MNULEGDCPYONBU-MQLHLVDXSA-N 0.000 description 1
- NRKHBJXGTNFZGX-UHFFFAOYSA-N COC1=C(CN2C(C)=CN=C2C2=CC=C(C=C2)C(F)(F)F)C=C(F)C=C1 Chemical compound COC1=C(CN2C(C)=CN=C2C2=CC=C(C=C2)C(F)(F)F)C=C(F)C=C1 NRKHBJXGTNFZGX-UHFFFAOYSA-N 0.000 description 1
- LZUVKZDRTBNTLH-UHFFFAOYSA-N COC1=C(CN2C(C)=CN=C2C2=CC=C(OC(F)(F)F)C=C2)C=C(C)C=C1 Chemical compound COC1=C(CN2C(C)=CN=C2C2=CC=C(OC(F)(F)F)C=C2)C=C(C)C=C1 LZUVKZDRTBNTLH-UHFFFAOYSA-N 0.000 description 1
- GYNMVDMBFKGCCR-QGZVFWFLSA-N C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)OC(F)(F)F Chemical compound C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)OC(F)(F)F GYNMVDMBFKGCCR-QGZVFWFLSA-N 0.000 description 1
- FVHFOYRHJUFWFT-MRXNPFEDSA-N C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C=1C=NC(=CC=1)C(F)(F)F Chemical compound C[C@@H](CC(=O)O)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C=1C=NC(=CC=1)C(F)(F)F FVHFOYRHJUFWFT-MRXNPFEDSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 101710147349 Carnitine transporter Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000015374 Central core disease Diseases 0.000 description 1
- 201000003728 Centronuclear myopathy Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- ZYSIAQDFLFFVJJ-MRXNPFEDSA-N ClC1=C(C=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1)F Chemical compound ClC1=C(C=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1)F ZYSIAQDFLFFVJJ-MRXNPFEDSA-N 0.000 description 1
- CWPAMLOOIUMUCY-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O Chemical compound ClC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O CWPAMLOOIUMUCY-UHFFFAOYSA-N 0.000 description 1
- IERITXNGOQFRTP-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)OC Chemical compound ClC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)OC IERITXNGOQFRTP-UHFFFAOYSA-N 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000017870 Congenital fiber-type disproportion myopathy Diseases 0.000 description 1
- 208000035902 Critical illness myopathy Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101100322888 Escherichia coli (strain K12) metL gene Proteins 0.000 description 1
- 208000001692 Esotropia Diseases 0.000 description 1
- 201000005538 Exotropia Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- LRFSWJDKLIGMQF-UHFFFAOYSA-N FC(OC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O)F Chemical compound FC(OC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O)F LRFSWJDKLIGMQF-UHFFFAOYSA-N 0.000 description 1
- IMECUCANUVGFRR-QGZVFWFLSA-N FC(OC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1)F Chemical compound FC(OC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)O)C)C=CC=C1)F IMECUCANUVGFRR-QGZVFWFLSA-N 0.000 description 1
- HDPLLLVBYLXKFZ-UHFFFAOYSA-N FC=1C=C(C=CC=1C(F)(F)F)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O Chemical compound FC=1C=C(C=CC=1C(F)(F)F)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)O HDPLLLVBYLXKFZ-UHFFFAOYSA-N 0.000 description 1
- OXPDMMVWSXUDCF-UHFFFAOYSA-N FC=1C=C(C=CC=1C(F)(F)F)C=1N(C(=CN=1)C)CC1=C(OCCCCC(C(=O)O)(C)C)C=CC=C1 Chemical compound FC=1C=C(C=CC=1C(F)(F)F)C=1N(C(=CN=1)C)CC1=C(OCCCCC(C(=O)O)(C)C)C=CC=C1 OXPDMMVWSXUDCF-UHFFFAOYSA-N 0.000 description 1
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 206010020740 Hyperproteinaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- WNJDGYOPALQKML-UHFFFAOYSA-N IC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)OC Chemical compound IC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(C=CC=C1)OC WNJDGYOPALQKML-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 238000001282 Kruskal–Wallis one-way analysis of variance Methods 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 1
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
- 101100355629 Mus musculus Ran gene Proteins 0.000 description 1
- 206010048654 Muscle fibrosis Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 102000034570 NR1 subfamily Human genes 0.000 description 1
- 108020001305 NR1 subfamily Proteins 0.000 description 1
- OKJHGOPITGTTIM-DEOSSOPVSA-N Naveglitazar Chemical compound C1=CC(C[C@H](OC)C(O)=O)=CC=C1OCCCOC(C=C1)=CC=C1OC1=CC=CC=C1 OKJHGOPITGTTIM-DEOSSOPVSA-N 0.000 description 1
- 208000034965 Nemaline Myopathies Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029323 Neuromyopathy Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 206010036802 Progressive external ophthalmoplegia Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 101100372319 Rattus norvegicus Utrn gene Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000785681 Sander vitreus Species 0.000 description 1
- 208000018675 Schwartz-Jampel syndrome Diseases 0.000 description 1
- 201000003222 Schwartz-Jampel syndrome 1 Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010059790 Ulnar nerve palsy Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 206010002537 anisometropia Diseases 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 1
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
- 229940112930 apidra Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 229960003362 carbutamide Drugs 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000007303 central core myopathy Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 206010010121 compartment syndrome Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 201000011477 congenital fiber-type disproportion Diseases 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 125000006003 dichloroethyl group Chemical group 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- GHJJKMSOYVEQSE-OAQYLSRUSA-N ethyl (3R)-3-methyl-6-[2-[[5-methyl-2-(4-methylphenyl)imidazol-1-yl]methyl]phenoxy]hexanoate Chemical compound C[C@@H](CC(=O)OCC)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C GHJJKMSOYVEQSE-OAQYLSRUSA-N 0.000 description 1
- BSRVHGGIANOHPV-HXUWFJFHSA-N ethyl (3R)-3-methyl-6-[2-[[5-methyl-2-(4-methylsulfanylphenyl)imidazol-1-yl]methyl]phenoxy]hexanoate Chemical compound C[C@@H](CC(=O)OCC)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)SC BSRVHGGIANOHPV-HXUWFJFHSA-N 0.000 description 1
- UWGUAVIOAJPZCJ-LJQANCHMSA-N ethyl (3R)-3-methyl-6-[2-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]imidazol-1-yl]methyl]phenoxy]hexanoate Chemical compound C[C@@H](CC(=O)OCC)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)OC(F)(F)F UWGUAVIOAJPZCJ-LJQANCHMSA-N 0.000 description 1
- ZPJZWGVYDBGYEE-LJQANCHMSA-N ethyl (3R)-3-methyl-6-[2-[[5-methyl-2-[4-(trifluoromethyl)phenyl]imidazol-1-yl]methyl]phenoxy]hexanoate Chemical compound C[C@@H](CC(=O)OCC)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F ZPJZWGVYDBGYEE-LJQANCHMSA-N 0.000 description 1
- LOONPEZSHOLLNE-LJQANCHMSA-N ethyl (3R)-6-[2-[[2-[4-(difluoromethoxy)phenyl]-5-methylimidazol-1-yl]methyl]phenoxy]-3-methylhexanoate Chemical compound FC(OC1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)OCC)C)C=CC=C1)F LOONPEZSHOLLNE-LJQANCHMSA-N 0.000 description 1
- YAIKDPBUALXGEV-LJQANCHMSA-N ethyl (3R)-6-[2-[[2-[4-(difluoromethyl)phenyl]-5-methylimidazol-1-yl]methyl]phenoxy]-3-methylhexanoate Chemical compound FC(C1=CC=C(C=C1)C=1N(C(=CN=1)C)CC1=C(OCCC[C@H](CC(=O)OCC)C)C=CC=C1)F YAIKDPBUALXGEV-LJQANCHMSA-N 0.000 description 1
- SSJQOTXWMLWHOK-MRVPVSSYSA-N ethyl (3R)-6-hydroxy-3-methylhexanoate Chemical compound OCCC[C@H](CC(=O)OCC)C SSJQOTXWMLWHOK-MRVPVSSYSA-N 0.000 description 1
- ZPJZWGVYDBGYEE-IBGZPJMESA-N ethyl (3S)-3-methyl-6-[2-[[5-methyl-2-[4-(trifluoromethyl)phenyl]imidazol-1-yl]methyl]phenoxy]hexanoate Chemical compound C[C@H](CC(=O)OCC)CCCOC1=C(C=CC=C1)CN1C(=NC=C1C)C1=CC=C(C=C1)C(F)(F)F ZPJZWGVYDBGYEE-IBGZPJMESA-N 0.000 description 1
- SSJQOTXWMLWHOK-QMMMGPOBSA-N ethyl (3S)-6-hydroxy-3-methylhexanoate Chemical compound OCCC[C@@H](CC(=O)OCC)C SSJQOTXWMLWHOK-QMMMGPOBSA-N 0.000 description 1
- UAIOJGGMISJMMY-LLVKDONJSA-N ethyl (3r)-3,7-dimethyloct-6-enoate Chemical compound CCOC(=O)C[C@H](C)CCC=C(C)C UAIOJGGMISJMMY-LLVKDONJSA-N 0.000 description 1
- RTMVZAZNAONVCQ-MRVPVSSYSA-N ethyl (3r)-3-methyl-6-oxohexanoate Chemical compound CCOC(=O)C[C@H](C)CCC=O RTMVZAZNAONVCQ-MRVPVSSYSA-N 0.000 description 1
- UAIOJGGMISJMMY-NSHDSACASA-N ethyl (3s)-3,7-dimethyloct-6-enoate Chemical compound CCOC(=O)C[C@@H](C)CCC=C(C)C UAIOJGGMISJMMY-NSHDSACASA-N 0.000 description 1
- RTMVZAZNAONVCQ-QMMMGPOBSA-N ethyl (3s)-3-methyl-6-oxohexanoate Chemical compound CCOC(=O)C[C@@H](C)CCC=O RTMVZAZNAONVCQ-QMMMGPOBSA-N 0.000 description 1
- GYDLKDMRVQUKRY-AATRIKPKSA-N ethyl (E)-6-bromo-2,2-dimethylhex-4-enoate Chemical compound BrC/C=C/CC(C(=O)OCC)(C)C GYDLKDMRVQUKRY-AATRIKPKSA-N 0.000 description 1
- LJDWRBCSOFXMTM-SOFGYWHQSA-N ethyl (E)-6-bromo-4-methylhex-4-enoate Chemical compound BrC/C=C(/CCC(=O)OCC)\C LJDWRBCSOFXMTM-SOFGYWHQSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 229950003707 farglitazar Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960001764 glibornuride Drugs 0.000 description 1
- RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 229950008402 glisentide Drugs 0.000 description 1
- NSJYMFYVNWVGON-UHFFFAOYSA-N glisentide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 description 1
- 229960003236 glisoxepide Drugs 0.000 description 1
- ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 229950000958 halofenate Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 208000014391 hyaline body myopathy Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 201000001948 hypertensive retinopathy Diseases 0.000 description 1
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 108700039926 insulin glulisine Proteins 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940060975 lantus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 1
- PIJFWZZQZKZLQP-FNORWQNLSA-N methyl (e)-6-bromo-4-methylhex-4-enoate Chemical compound COC(=O)CC\C(C)=C\CBr PIJFWZZQZKZLQP-FNORWQNLSA-N 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004769 mitochondrial stress Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 229950001135 muraglitazar Drugs 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 208000029372 muscular lipidosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000003274 myotonic effect Effects 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- OXCREIAATRYJNU-UHFFFAOYSA-N n-benzyl-2-methoxyaniline Chemical compound COC1=CC=CC=C1NCC1=CC=CC=C1 OXCREIAATRYJNU-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229950003494 naveglitazar Drugs 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
- 229950001628 netoglitazone Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- MNULEGDCPYONBU-UHFFFAOYSA-N oligomycin A Natural products CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
- 238000012015 optical character recognition Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000006611 pharmacological activation Effects 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000024977 response to activity Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229950010764 rivoglitazone Drugs 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000001392 short chain acyl-CoA dehydrogenase deficiency Diseases 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 231100000399 thyrotoxic Toxicity 0.000 description 1
- 230000001897 thyrotoxic effect Effects 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- NIDHFQDUBOVBKZ-NSCUHMNNSA-N trans-hex-4-enoic acid Chemical compound C\C=C\CCC(O)=O NIDHFQDUBOVBKZ-NSCUHMNNSA-N 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 208000036722 ulnar neuropathy Diseases 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238629P | 2015-10-07 | 2015-10-07 | |
| US201562243263P | 2015-10-19 | 2015-10-19 | |
| US201662352348P | 2016-06-20 | 2016-06-20 | |
| PCT/US2016/055521 WO2017062468A1 (en) | 2015-10-07 | 2016-10-05 | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2906379T3 true ES2906379T3 (es) | 2022-04-18 |
Family
ID=57200096
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16785611T Active ES2906379T3 (es) | 2015-10-07 | 2016-10-05 | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
| ES20193962T Active ES2949852T3 (es) | 2015-10-07 | 2016-10-05 | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
| ES20193960T Active ES2988059T3 (es) | 2015-10-07 | 2016-10-05 | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20193962T Active ES2949852T3 (es) | 2015-10-07 | 2016-10-05 | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
| ES20193960T Active ES2988059T3 (es) | 2015-10-07 | 2016-10-05 | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US10399958B2 (enExample) |
| EP (3) | EP3795566B1 (enExample) |
| JP (2) | JP6657413B2 (enExample) |
| KR (2) | KR102667385B1 (enExample) |
| CN (3) | CN113004205B (enExample) |
| AU (3) | AU2016333963C1 (enExample) |
| BR (1) | BR112018006866B1 (enExample) |
| CA (1) | CA3000431A1 (enExample) |
| CO (1) | CO2018004473A2 (enExample) |
| DK (1) | DK3359528T3 (enExample) |
| EA (1) | EA037371B1 (enExample) |
| ES (3) | ES2906379T3 (enExample) |
| HU (1) | HUE058154T2 (enExample) |
| IL (3) | IL258225B (enExample) |
| JO (3) | JO3738B1 (enExample) |
| MA (2) | MA52098A (enExample) |
| MX (3) | MX380281B (enExample) |
| MY (1) | MY203081A (enExample) |
| PH (1) | PH12018500762A1 (enExample) |
| PL (1) | PL3359528T3 (enExample) |
| PT (1) | PT3359528T (enExample) |
| SG (1) | SG10201906400SA (enExample) |
| TW (3) | TWI730006B (enExample) |
| UA (1) | UA122237C2 (enExample) |
| WO (1) | WO2017062468A1 (enExample) |
| ZA (4) | ZA201802029B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113004205B (zh) | 2015-10-07 | 2024-07-02 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
| ES2861503T3 (es) | 2016-04-13 | 2021-10-06 | Mitobridge Inc | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
| JP7017563B2 (ja) | 2016-10-05 | 2022-02-08 | ミトブリッジ，インコーポレーテッド | Ｐｐａｒアゴニスト化合物の結晶性および塩形態 |
| KR20190062502A (ko) * | 2016-10-05 | 2019-06-05 | 미토브리지, 인크. | 급성 신장 손상을 치료하는 방법 |
| WO2021046081A1 (en) * | 2019-09-05 | 2021-03-11 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| BR112023025221A2 (pt) | 2021-06-02 | 2024-02-27 | Astellas Pharma Inc | Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| WO2025207099A1 (en) | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228281A (en) | 1977-09-23 | 1980-10-14 | Ciba-Geigy Corporation | Dicarboxylic acids containing triazine rings |
| DE4123341A1 (de) * | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| CN1348442A (zh) | 1999-02-26 | 2002-05-08 | 默克公司 | 新的磺胺化合物及其应用 |
| GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| ATE447557T1 (de) | 2000-08-17 | 2009-11-15 | Pfizer Ltd | Substitutuierte imidazole als tafia inhibitoren |
| CA2495943C (en) * | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| JP4691988B2 (ja) | 2002-10-03 | 2011-06-01 | 小野薬品工業株式会社 | Ｌｐａ受容体拮抗剤 |
| WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
| KR20060080214A (ko) | 2003-09-26 | 2006-07-07 | 니뽄 다바코 산교 가부시키가이샤 | 잔여 리포프로테인 생산 저해 방법 |
| RU2007112688A (ru) | 2004-09-06 | 2008-10-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные 4-аминометилбензамина и их применение в качестве ингибиторов фактора viia |
| EP1863772A1 (en) | 2005-02-15 | 2007-12-12 | F.Hoffmann-La Roche Ag | Amide derivatives as ppar activators |
| AU2006287521A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | PPARactive compounds |
| EP1991544B1 (en) | 2006-01-30 | 2018-08-15 | vTv Therapeutics LLC | Substituted imidazole derivatives and their use as ptpase inhibitors |
| EP2001851A2 (en) | 2006-03-28 | 2008-12-17 | Novartis AG | Amide derivatives and their application for the treament of g protein related diseases |
| US8404726B2 (en) | 2006-04-18 | 2013-03-26 | Nippon Chemiphar Co. Ltd. | Activating agent for peroxisome proliferator activated receptor δ |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| CN101085772A (zh) * | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
| EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| GB2460784A (en) | 2007-03-07 | 2009-12-16 | Dong A Pharmtech Co Ltd | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition |
| JP2008285452A (ja) | 2007-05-21 | 2008-11-27 | Ono Pharmaceut Co Ltd | ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 |
| AU2008345009A1 (en) | 2007-12-28 | 2009-07-09 | The Salk Institute For Biological Studies | Methods for enhancing muscle performance and tone |
| ES2607482T3 (es) | 2012-08-28 | 2017-03-31 | Koc Universitesi | Placa ósea |
| CA2908695A1 (en) * | 2013-04-05 | 2014-10-09 | Salk Institute For Biological Studies | Ppar agonists |
| ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
| WO2016057658A1 (en) | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| CN113004205B (zh) | 2015-10-07 | 2024-07-02 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
| ES2861503T3 (es) | 2016-04-13 | 2021-10-06 | Mitobridge Inc | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
| KR20190062502A (ko) | 2016-10-05 | 2019-06-05 | 미토브리지, 인크. | 급성 신장 손상을 치료하는 방법 |
| JP7017563B2 (ja) * | 2016-10-05 | 2022-02-08 | ミトブリッジ，インコーポレーテッド | Ｐｐａｒアゴニスト化合物の結晶性および塩形態 |
| LT3562822T (lt) * | 2016-12-30 | 2021-06-10 | Mitobridge, Inc. | Poli-adp ribozės polimerazės (parp) inhibitoriai |
-
2016
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active Active
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 MX MX2018004295A patent/MX380281B/es unknown
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active Active
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 CN CN202110286947.3A patent/CN113024467B/zh active Active
- 2016-10-05 CA CA3000431A patent/CA3000431A1/en active Pending
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 MX MX2020011100A patent/MX392523B/es unknown
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 MY MYPI2018000444A patent/MY203081A/en unknown
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/en active Active
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-05 MX MX2020011099A patent/MX392524B/es unknown
- 2016-10-05 ES ES20193960T patent/ES2988059T3/es active Active
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 EP EP20193960.0A patent/EP3770146B1/en active Active
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/en active Active
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/en not_active Ceased
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
-
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
-
2019
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
-
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-09-14 JO JOP/2020/0231A patent/JOP20200231A1/ar unknown
- 2020-09-14 JO JOP/2020/0230A patent/JOP20200230A1/ar unknown
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
-
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
-
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
-
2024
- 2024-01-25 US US18/422,793 patent/US20240417383A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2906379T3 (es) | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos | |
| EA039833B1 (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
| HK1257907B (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |